875-P: Baseline Characteristics for FINE-ONE—A Randomized Phase III Trial Assessing Finerenone in People with T1D and CKD
Hiddo J.L. Heerspink(University Medical Center Groningen), Andreas L. Birkenfeld(Helmholtz Zentrum München), Linong Ji(Peking University), KATHERINE R. TUTTLE, Jay S. Skyler(University of Miami), Per‐Henrik Groop(University of Helsinki), Janet B. McGill(Washington University in St. Louis), SYLVIA ROSAS, Robert Lawatscheck(Bayer (Germany)), Peter Rossing(Steno Diabetes Centers), Richard E. Pratley(Translational Research Institute for Metabolism and Diabetes), Markus F. Scheerer(Bayer (Germany)), Helen M. Colhoun(Edinburgh Cancer Research), David Cherney
Cited by 0
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
|The Lancet|2004|3.8k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k